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M A J O R A R T I C L E
Heterologous Prime-Boost Vaccination Using an
AS03B-Adjuvanted Inﬂuenza A(H5N1) Vaccine
in Infants and Children <3 Years of Age
Terry Nolan,1,2 Patricia Izurieta,7 Bee-Wah Lee,9 Poh Chong Chan,10 Helen Marshall,3,4,5 Robert Booy,6
Mamadou Drame,11 and David W. Vaughn8
1Murdoch Childrens Research Institute, 2Melbourne School of Population and Global Health, University of Melbourne, Victoria, 3Vaccinology and
Immunology Research Trials Unit, Women’s and Children’s Hospital, North Adelaide, 4School of Paediatrics and Reproductive Health, 5Robinson Research
Institute, University of Adelaide, and 6Children’s Hospital at Westmead, National Centre for Immunisation Research and Surveillance, Australia;
7GlaxoSmithKline Vaccines, Wavre, and 8GlaxoSmithKline Vaccines, Rixensart, Belgium; 9Mount Elizabeth Medical Centre, and 10National University
Hospital, Singapore; and 11GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania
Background. Protecting young children from pandemic inﬂuenza should also reduce transmission to suscepti-
ble adults, including pregnant women.
Methods. An open study assessed immunogenicity and reactogenicity of a heterologous booster dose of A/
turkey/Turkey/1/2005(H5N1)-AS03B (AS03B is an Adjuvant System containing α-tocopherol and squalene in an
oil-in-water emulsion [5.93 mg tocopherol]) in infants and children aged 6 to < 36 months that was given 6 months
following 2-dose primary vaccination with A/Indonesia/05/2005(H5N1)-AS03B. Vaccines contained 1.9 µg of hem-
agglutinin antigen and AS03B. Hemagglutinin inhibition (HI) responses, microneutralization titers, and antineura-
minidase antibody levels were assessed for 6 months following the booster vaccination.
Results. For each age stratum (deﬁned on the basis of the subject’s age at ﬁrst vaccination as 6 to < 12 months,
12 to < 24 months, and 24 to < 36 months) and overall (n = 113), European inﬂuenza vaccine licensure criteria
were fulﬁlled for responses to A/turkey/Turkey/1/2005(H5N1) 10 days following the booster vaccination. Local
pain and fever increased with consecutive doses. Anamnestic immune responses were demonstrated for HI, neu-
tralizing, and antineuraminidase antibodies against vaccine-homologous/heterologous strains. Antibody re-
sponses to vaccine-homologous/heterologous strains persisted in all children 6 months following the booster
vaccination.
Conclusions. Prevaccination of young children with a clade 2 strain inﬂuenza A(H5N1) AS03-adjuvanted
vaccine followed by heterologous booster vaccination boosted immune responses to the homologous strain
and a related clade, with persistence for at least 6 months. The results support a prime-boost vaccination ap-
proach in young children for pandemic inﬂuenza preparedness.
Clinical Trials Registration. NCT01323946.
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Avian inﬂuenza A(H5N1) was identiﬁed as a cause of
death in poultry in 1996, with the ﬁrst human cases
of infection recorded in 1997 [1]. From 2003 until
January 2014, inﬂuenza A(H5N1) has caused 650
cases of inﬂuenza in humans [2]. Around 90% of
cases have occurred in individuals <40 years of age,
with a case-fatality rate of 60% [3]. Although not yet
able to spread efﬁciently between humans, inﬂuenza
A(H5N1) is considered to be a potential threat for a fu-
ture inﬂuenza pandemic [4]. Globally, preparatory ac-
tivities are being undertaken to develop vaccines and
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vaccination strategies that could provide widespread protection
in the event of a pandemic due to inﬂuenza A(H5N1) [5].
Pandemic preparedness strategies include the prepandemic
vaccination of a population, to reduce attack rates in the event
of a pandemic, or the release of stockpiled prepandemic vaccine
at the start of a pandemic, to prime or protect recipients until
strain-matched vaccine becomes available. Use of a prepandemic
vaccine could be successful if the vaccine strain induces a broad
immune response that includes a response to the pandemic
strain. In the event of a pandemic, subsequent vaccination with
a pandemic-strain-speciﬁc vaccine would boost the immune re-
sponse, improving protection against the pandemic strain.
An inactivated, split-virion recombinant inﬂuenza A(H5N1)
vaccine with 3.75 µg hemagglutinin (HA) combined with the
proprietary Adjuvant System 03 (hereafter, “H5N1-AS03”; Pre-
pandrix™ GlaxoSmithKline Vaccines, Dresden, Germany) is
licensed for use as a prepandemic vaccine for adults aged ≥18
years of age in the European Union and other countries. A sec-
ond version of H5N1-AS03 (with the same formulation but
manufactured by GlaxoSmithKline Vaccines, Laval, Canada)
has been approved for use in pandemic response in the Europe-
an Union (as Pumarix™), Canada (as Arepanrix™H5N1), and
in the United States as of November 2013 [6].
Children play an important role in inﬂuenza outbreaks, hav-
ing high attack rates and contributing to transmission among
their families, schools, and day care centers [7, 8]. Thus, strate-
gies to mitigate inﬂuenza virus infection among children could
have important effects not only in protecting children, but in
reducing transmission to adults, including pregnant women.
H5N1-AS03 had an acceptable clinical safety proﬁle [9] and
showed good immunogenicity, with broad clade and subclade
antibody cross-reactivity after 2 doses in adults [10–13]. In chil-
dren aged 3–9 years, 2 doses of H5N1-AS03 (full dose or half
dose) were immunogenic for homologous and heterologous
vaccine strains [14]. While H5N1-AS03 candidates have been
studied extensively in older children and adults, they had not
been assessed in infants and younger children, who are particu-
larly vulnerable to inﬂuenza. We evaluated the immunogenicity,
reactogenicity, and safety of H5N1-AS03, using a heterologous
prime-boost vaccination schedule, in young children aged 6 to
<36 months.
METHODS
Study Design and Objectives
This phase 2 study was open in design and conducted at 6
centers in Australia and 2 centers in Singapore between 18
April 2011 and 2 November 2012 (clinical trials registration:
NCT01323946). The study was conducted according to good
clinical practice and in accordance with the Declaration of
Helsinki. The protocol and associated documents were reviewed
and approved by local institutional review boards. Written
informed consent was obtained from the parents/guardians of
children before enrollment.
The primary study objective was to assess whether a heterolo-
gous booster dose of A/turkey/Turkey/1/2005(H5N1)-AS03B
(AS03B contains half the dose of α-tocopherol contained in
AS03) given 6 months following a 2-dose primary vaccination se-
ries with A/Indonesia/05/2005(H5N1)-AS03B elicited an antibody
response that met the European Medicines Agency Committee
for Medicinal Products for Human Use (CHMP) targets for inﬂu-
enza vaccine seroconversion rate, seroprotection rate, and mean
geometric increase based on the hemagglutinin inhibition (HI)
responses to A/turkey/Turkey/1/2005(H5N1) 10 days following
the booster vaccination. The CHMP criteria were fulﬁlled if the
point estimate for the seroconversion rate was >40%, the point es-
timate for the seroprotection rate was >70%, or the point estimate
for the mean geometric increase was >2.5.
Secondary and tertiary study objectives included the assessment
of immunogenicity in age-based subgroups, immunogenicity in
terms of microneutralization and antineuraminidase (anti-NA)
antibody titers, reactogenicity and safety of the study vaccines,
and assessment of persistence of the immune response to day 364.
All participants received 2 priming doses 21 days apart of the
A/Indonesia/05/2005(H5N1)- AS03B candidate vaccine and a
booster dose of the A/turkey/Turkey/1/2005(H5N1)-AS03B
candidate vaccine on day 182.
Participants were stratiﬁed into 3 age strata (deﬁned on the
basis of the subject’s age at ﬁrst vaccination as 6 to < 12 months,
12 to <24 months, and 24 to <36 months) in a 2:1:1 ratio. The
planned ratio could not be achieved because of difﬁculties in re-
cruiting infants. A protocol amendment allowed the age stratiﬁca-
tion ratio to differ from the ratio speciﬁed in the original protocol.
Study Participants
Participants were healthy children aged 6 to <36 months. Children
were excluded from participation if they were immunosuppressed
or had received immunosuppressants or other immune-modifying
drugs for >14 days during the 6-month period before receipt of the
ﬁrst vaccine dose or if they had a history of allergy or hypersensi-
tivity to any component of the vaccines, such as egg protein or thi-
merosal. Children were excluded if administration of any vaccine
was planned ≤30 days before or 21 days after any study vaccine
administration; if they had a history of any neurological disorders
or seizures or a clinically signiﬁcant pulmonary, cardiovascular,
hepatic, or renal functional abnormality; or if they had received
immunoglobulins or other blood products ≤3 months before en-
rollment. Children who had received an inﬂuenza A(H5N1) vac-
cine at any time and those with a history of physician-conﬁrmed
inﬂuenza A(H5N1) infection were also excluded.
Vaccines
The pandemic inﬂuenza vaccines (A/Indonesia/05/2005 and A/
turkey/Turkey/1/2005) were 2-component vaccines presented










in 2 multidose vials, one containing antigen and the other con-
taining adjuvant. One pediatric dose of the vaccine, after mixing
(0.25 mL), contained 1.9 µg of hemagglutinin antigen (HA) and
AS03B (which contained 5.93 mg of α-tocopherol and squalene
in an oil-in-water emulsion). Vaccines were administered intra-
muscularly into the anterior thigh (for children <12 months of
age) or deltoid (for those ≥12 months of age), alternating sides
for each dose.
Immunogenicity Assessment
The humoral immune response to vaccination was assessed on
days 0, 42, 182, 192 (10 days following booster vaccination), and
364.
HI antibodies for the A/Indonesia/05/2005 and A/turkey/
Turkey/1/2005 strains were measured as previously described
but were modiﬁed by using horse erythrocytes rather than
avian erythrocytes [15–18]. The lowest dilution tested was
1:10. The titration end point was the highest dilution step that
showed complete inhibition (100%) of hemagglutination. HI
antibody titers of ≥1:40 were considered indicative of seropro-
tection [19, 20].
The viral microneutralization assay for A/Indonesia/05/2005
and A/turkey/Turkey/1/2005 strains was performed as previ-
ously described [15, 17]. In brief, a standardized amount of
virus was mixed with serial 2-fold dilutions of serum samples
to allow antibody/virus binding. The mixture containing
bound antibody was added to Madin-Darby canine kidney
cell cultures and incubated for 7 days at 33°C. Viral replication
was visualized by hemagglutination of chicken red blood cells.
The 50% neutralization titer of a serum was calculated. The
assay cutoff was 1:28.
Anti-NA antibodies for the A/Indonesia/05/2005(H5N1)
strain were measured in a randomly selected subset of 50%
of children as previously described [21]. The test is based on
enzymatic activity of NA, which releases neuraminic acid
from fetuin. After cleavage of the terminal neuraminic acid by
NA, β-D-galactose-N-acetylgalactosamine is unmasked, and
peanut agglutinin can bind to this galactose residue. By using
peroxidase-labeled peanut agglutinin, the reaction can be de-
tected and quantiﬁed in a substrate reaction. The intensity of
the substrate reaction is inversely proportional to the quantity
of antibodies in the serum.
All serological tests were performed at a GlaxoSmithKline
Vaccines’ central laboratory, using standardized, validated
procedures.
Safety and Reactogenicity Assessment
Local (injection site pain, redness, and swelling) and general
(drowsiness, fever [temperature ≥38°C by any measurement
route], irritability/fussiness, loss of appetite, diarrhea, and vom-
iting) symptoms were recorded on diary cards for 7 days after
each dose. All other (unsolicited) adverse events (AEs) were
recorded for 21 days after each dose and from the ﬁrst dose
until day 84. AEs were graded on a 3-point scale in which “0”
denoted no AEs, “1” denoted mild AEs, “2” denoted moderate
AEs, and “3” denoted severe AEs. All injection site symptoms
were considered to be vaccine related. For all other symptoms,
potential causal relationships with vaccination were determined
by the site investigator. Serious AEs (SAEs), potential immune-
mediated diseases (pIMDs) and medically attended AEs, de-
ﬁned as hospitalization, an emergency department visit, or a
visit to or frommedical personnel for any reason, were recorded
throughout the study until the day 364 contact.
The use of medications, including antipyretic medication,
was recorded until day 203.
Statistical Analyses
The primary cohorts for the assessment of immunogenicity at
each time point were the per-protocol cohorts, which included
all eligible children who complied with protocol-deﬁned proce-
dures and who had HI assay results for the speciﬁc time point
under evaluation.
The seroprotection rate was deﬁned as the percentage of chil-
dren with a serum inﬂuenza A(H5N1) HI antibody titer of
≥1:40. The seroconversion rate was deﬁned as the percentage
of initially seronegative participants with a postvaccination
titer of ≥1:40 or the percentage of initially seropositive partici-
pants with a ≥4-fold increase in titer. The mean geometric in-
crease was deﬁned as the geometric mean of the within-subject
ratios of the postvaccination reciprocal HI titer to the prevacci-
nation (day 0) reciprocal HI titer. The booster seroconversion
rate was deﬁned as the seroconversion rate relative to the pre-
booster (day 182) blood sample. The booster factor was deﬁned
as the geometric mean of the within-subject ratios of the post-
booster reciprocal HI titer to the prebooster (day 182) reciprocal
HI titer. A vaccine/booster response for serum neutralizing
antibody titers was deﬁned a ≥4-fold increase in postvaccina-
tion titer relative to day 0 (day 182 for a booster response).
Anti-NA antibodies were assessed in terms of seropositivity
and geometric mean titers (GMTs).
The primary analysis of safety was conducted on the total
vaccinated cohort, which included all children who received
at least 1 vaccine administration during the study.
Analyses were performed using SAS software, version 9.2
(SAS Institute, Cary, NC), and StatXact-8.1.
RESULTS
Study Participants
There were 113 children enrolled and vaccinated, of whom 109
(96.5%) completed the vaccination phase (to day 203) of the
study. No child was withdrawn due to an AE (Figure 1). Sex
and racial heritage of participants were similar across age strata
(Table 1).












The primary objective was met: for each age stratum and overall,
all CHMP criteria were fulﬁlled for responses to A/turkey/
Turkey/1/2005(H5N1) 10 days after receipt of a heterologous
booster dose of A/turkey/Turkey/1/2005(H5N1)-AS03B that
was given 6 months after 2-dose primary vaccination with A/In-
donesia/05/2005(H5N1)-AS03B (Table 2).
Immunogenicity to A/Turkey/Turkey/01/2005(H5N1)
Before and After the Booster Dose
The seroprotection rate for the heterologous strain (A/turkey/
Turkey/1/2005[H5N1]) was 1.2% before priming but 97.6% at
day 182 after 2 doses of A/Indonesia/05/2005(H5N1)-AS03B
(Table 2). Ten days after administration of the heterologous
booster vaccination (A/turkey/Turkey/1/2005[H5N1]-AS03B),
all children had HI titers of ≥1:40, and compared with the
prebooster time point, 98.8% of all children seroconverted.
HI GMTs were higher at day 182 than before vaccination and
increased markedly in all age strata 10 days following boos-
ter vaccination (Figure 2). The booster factor was 25.7 for
children aged 6 to < 12 month olds, 21.5 for those aged 12
to < 24 months, and 20.5 for those aged 24 to < 36 months
(Table 2).
Figure 1. Participant ﬂow through the study. Abbreviation: PP, per protocol.
Table 1. Demographic Characteristics, by Age, for the Total
Vaccinated Cohort at Dose 1
Characteristic
6 to < 12 mo
(n = 46)
12 to < 24 mo
(n = 34)
24 to < 36 mo
(n = 33)
Age, mo
Mean ± SD 8.3 ± 1.56 16.1 ± 3.44 29.6 ± 3.38
Median (range) 8 (6–11) 15 (12–23) 30 (24–35)
Sex, no. (%)
Female 25 (54.3) 19 (55.9) 19 (57.6)
Male 21 (45.7) 15 (44.1) 14 (42.4)
Ethnicity, no. (%)
Southeast Asian 34 (73.9) 26 (76.5) 22 (66.7)
White 12 (26.1) 8 (23.5) 9 (27.3)
Other 0 (0) 0 (0) 2 (6.1)










Table 2. Hemagglutinin Inhibition (HI) Antibodies Against A/Turkey/Turkey/01/2005(H5N1) and A/Indonesia/5/2005(H5N1), by Age, in the
Per Protocol Cohorts for Immunogenicity
Vaccine, Age, Time Pointa
SC Rate/BSC Rateb SP Ratec MGI/BFd
Subjects, No. Subjects, % (95% CI)
Subjects With a
Titer ≥ 1:40, % (95% CI) Value (95% CI)
A/turkey/Turkey/01/2005(H5N1)
6 to <12 mo
Before 33 . . . 0.0 (0.0; 10.6) . . .
Day 182 33 93.9 (79.8; 99.3) 93.9 (79.8; 99.3) 16.5 (12.8; 21.4)
Day 192 33 97.0 (84.2; 99.9) 100 (89.4; 100) 25.7 (18.4; 35.7)
Day 364 41 100 (91.4; 100) 100 (91.4; 100) 19.9 (15.2; 26.1)
12 to <24 mo
Before 24 . . . 0.0 (0.0; 14.2) . . .
Day 182 21 95.2 (76.2; 99.9) 100 (83.9; 100) 14.8 (10.8; 20.1)
Day 192 21 100 (83.9; 100) 100 (83.9; 100) 21.5 (16.4; 28.2)
Day 364 26 100 (86.8; 100) 100 (87.2; 100) 16.4 (12.6; 21.4)
24 to <36 mo
Before 29 . . . 3.4 (0.1; 17.8) . . .
Day 182 29 96.6 (82.2; 99.9) 100 (88.1; 100) 15.6 (12.5; 19.5)
Day 192 29 100 (88.1; 100) 100 (88.1; 100) 20.5 (16.2; 26.1)
Day 364 32 87.5 (71.0; 96.5) 100 (89.1; 100) 9.5 (7.2; 12.5)
All
Before 86 . . . 1.2 (0.0; 6.3) . . .
Day 182 83 95.2 (88.1; 98.7) 97.6 (91.6; 99.7) 15.8 (13.6; 18.2)
Day 192 83 98.8 (93.5; 100) 100 (95.7; 100) 22.7 (19.3; 26.8)
Day 364 99 96.0 (90.0; 98.9) 100 (96.4; 100) 14.9 (12.6; 17.6)
A/Indonesia/5/2005(H5N1)
6 < 12 mo
Before 33 . . . 0.0 (0.0; 10.6) . . .
Day 42 32 100 (89.1; 100) 100 (89.1; 100) 189.0 (149.2; 239.6)
Day 182 33 97.0 (84.2; 99.9) 97.0 (84.2; 99.9) 32.0 (25.1; 40.8)
Day 192 33 100 (89.4; 100) 100 (89.4; 100) 432.8 (354.5; 528.3)
Day 364 41 100 (91.4; 100) 100 (91.4; 100) 293.1 (233.6; 367.6)
12 < 24 mo
Before 24 . . . 0.0 (0; 14.2) . . .
Day 42 24 100 (85.8; 100) 100 (85.8; 100) 267.3 (198.1; 360.8)
Day 182 21 100 (83.9; 100) 100 (83.9; 100) 29.5 (22.6; 38.3)
Day 192 21 100 (83.9; 100) 100 (83.9; 100) 306.9 (221.6; 425.1)
Day 364 27 100 (87.2; 100) 100 (87.2; 100) 211.2 (153.8; 289.8)
24 < 36 mo
Before 29 . . . 0.0 (0; 11.9) . . .
Day 42 29 100 (88.1; 100) 100 (88.1; 100) 208.9 (166.5; 262.2)
Day 182 29 100 (88.1; 100) 100 (88.1; 100) 26.7 (22.6; 31.6)
Day 192 29 100 (88.1; 100) 100 (88.1; 100) 321.2 (250.9; 411.4)
Day 364 32 100 (89.1; 100) 100 (89.1; 100) 133.7 (101.0; 176.8)
All
Before 86 . . . 0.0 (0.0; 4.2) . . .
Day 42 85 100 (95.8; 100) 100 (95.8; 100) 215.7 (187.1; 248.7)
Day 182 83 98.8 (93.5; 100) 98.8 (93.5; 100) 29.4 (25.9; 33.4)
Day 192 83 100 (95.7; 100) 100 (95.7; 100) 357.5 (310.5; 411.7)
Day 364 100 100 (96.4; 100) 100 (96.4; 100) 208.7 (177.2; 245.7)
Abbreviations: BF, booster factor; BSC, booster seroconversion; CI, confidence interval; MGI, mean geometric increase; SC, seroconversion.
a
“Before” denotes before vaccination; “day 42,” 21 days after dose 2; “day 182,” before booster; “day 192,” 10 days after the booster; and “day 364,” 6 months
after the booster.
b A/turkey/Turkey/01/2005(H5N1) only: percentage of seronegative participants with a postvaccination/booster titer of ≥1:40 or the percentage of initially seropositive
participants with a ≥4-fold increase in titer.
c The seroprotection (SP) rate is defined as the percentage with HI antibody titer of ≥1:40.
d A/turkey/Turkey/01/2005(H5N1) only: geometric mean of the within-subject ratios of the postvaccination/postbooster reciprocal HI titer to the prevaccination/
prebooster reciprocal HI titer.










All participants had neutralizing antibody responses to the
heterologous strain (A/turkey/Turkey/01/2005[H5N1]) before
the booster dose. Neutralizing antibody responses persisted
until day 364 (Supplementary Table 1). GMTs of neutralizing
antibodies increased markedly following booster vaccination,
and at least 96.4% of children in each age stratum had a booster
response to the A/turkey/Turkey/01/2005(H5N1)-AS03B strain
(Supplementary Table 1).
Immunogenicity to A/Indonesia/05/2005(H5N1) Following
Primary and Heterologous Booster Vaccinations
After 2 doses of A/Indonesia/05/2005(H5N1)-AS03B, all
children seroconverted, and all had HI titers of ≥1:40 to
A/Indonesia/05/2005(H5N1) (Table 2). The mean geometric
increase after vaccination was at least 189.0 for each age stratum.
Postvaccination HI GMTs were similar across age strata
(Figure 2).
A/Indonesia/05/2005(H5N1) HI GMTs decreased over
time but remained above baseline levels at day 182. Ten days
after receipt of the heterologous A/turkey/Turkey/1/2005-
H5N1-AS03B booster dose, A/Indonesia/05/2005(H5N1) HI
GMTs increased to at least postprimary (day 42) levels (Fig-
ure 2). The post-booster mean geometric increase for A/Indo-
nesia/05/2005(H5N1) was 432.8 for children aged 6 to < 12
months, 306.9 for those aged 12 to < 24 months, and 321.2
for those aged 12 to < 36 months (Table 2).
All participants were seropositive and had a vaccine response for
neutralizing antibodies to A/Indonesia/05/2005(H5N1) at day 42
(Supplementary Table 1). All participants remained seropositive
before and after the heterologous booster vaccination, until day
364. Neutralizing GMTs were similar across age strata. The A/tur-
key/Turkey/1/2005(H5N1)-AS03B booster dose induced postboos-
ter A/Indonesia/05/2005(H5N1) HI titers that were at least as high
as titers observed after primary vaccination (day 42).
All participants were seropositive for anti-NA antibodies
against A/Indonesia/05/2005(H5N1) at day 42 (Supplementary
Table 2). Prior to the booster vaccination, 97.6% of all partici-
pants were seropositive for anti-NA antibodies; the percentage
increased to 100% after the booster vaccination and persisted
until day 364.
Reactogenicity and Safety
Pain was the most frequently reported local solicited symptom
after each dose and appeared to increase in frequency with con-
secutive doses (Figure 3). Redness was reported for 3.6% of chil-
dren after dose 1, 5.4% after dose 2, and 16.7% after the booster
dose. Swelling was reported for 2.7% of children after dose 1,
3.6% after dose 2, and 10.2% after the booster dose. No grade
3 redness or swelling was reported during the study.
Irritability/fussiness was the most frequently reported general
symptom (Figure 4). The incidence of fever appeared to in-
crease with consecutive doses but was similar across age strata
(Figure 3). After the booster vaccination, fever was reported in
50% of all participants, and grade 3 fever (temperature, ≥39.0°C)
was reported in 10.2% of participants. There were no cases
of fever involving a temperature of ≥40.0°C after dose 1 or 2,
and 2 participants (1.9%) reported fever with a temperature
of ≥40.0°C following the booster vaccination. No febrile con-
vulsions were reported.
Between days 0 and 203, 79.6% subjects received an antipy-
retic medication, with the majority (94%) receiving it for ther-
apeutic purposes. The frequency of antipyretic use increased
with each dose, with 31.0% receiving treatment following dose
1, 50.0% receiving treatment following dose 2, and 65.7% receiv-
ing treatment following dose 3. Other unsolicited AEs consid-
ered to be causally related to study vaccination were reported
≤21 days after any dose for 28.3% (95% conﬁdence interval
[CI], 16.0%–43.5%) of infants aged 6 to < 12 months, 14.7%
(95% CI, 5.0%–31.1%) aged 12 to < 24 months, and 21.2%
(95% CI, 9.0%–38.9%) aged 24 to < 36 months. The most fre-
quently reported related symptoms were rhinorrhea, cough,
Figure 2. Hemagglutinin inhibition (HI) geometric mean titers against
A/Indonesia/05/2005(H5N1) and A/turkey/Turkey/01/2005(H5N1), by age,
in the per protocol cohorts for immunogenicity. Vaccination occurred on
days 0, 21, and 18.










nasopharyngitis, rhinitis, and upper respiratory tract infection.
There were 2 grade 3 causally related unsolicited events reported
≤21 days after any vaccine dose: nasopharyngitis (onset 2 days
following dose 2) and swelling of the face (onset on the day of
dose 1, with no recurrence after subsequent doses). A similar
distribution of AEs was reported from days 0 through 84.
Between days 0 and 364, SAEs were reported for 9 children,
none of which were considered to be vaccine related. All partic-
ipants recovered. During the same period, unsolicited medically
attended AEs were reported in 60.2% (95% CI, 50.5%–69.3%) of
all participants. No pIMDs or deaths were reported.
DISCUSSION
In young children primed with a 2-dose series of A/Indonesia/
05/2005(H5N1)-AS03B and boosted with a single dose of A/
turkey/Turkey/1/2005(H5N1)-AS03B, an anamnestic response
was demonstrated in terms of HI, neutralizing, and anti-NA
antibodies against both strains. The booster vaccination in-
duced HI antibody responses for the A/turkey/Turkey/1/2005
(H5N1) strain that fulﬁlled CHMP criteria overall and for
each age stratum. Six months after the booster dose, all children
had HI titers of ≥1:40 and remained seropositive for neutraliz-
ing antibodies against homologous and heterologous strains
and for anti-NA for the homologous strain. These data suggest
that, as observed in older populations, a 2-dose series of H5N1-
AS03B confers a primary immune response and induces broad
cross-reactive immunity in young children, with immune re-
sponses that persist for at least 6 months.
We administered a booster vaccination after 2 priming
doses to assess priming by demonstration of an anamnestic re-
sponse. Reactogenicity and fever, as well as antipyretic use, were
Figure 3. Injection site pain and fever after vaccination by age and dose, in the total vaccinated cohort. Grade 3 pain is deﬁned as “cried when limb was
moved/spontaneously painful.”










Figure 4. General symptoms following vaccination, by age and dose, in the total vaccinated cohort. Grade 3 is deﬁned as “preventing normal activity for
diarrhea/vomiting, drowsiness, and loss of appetite and as crying that could not be comforted/prevented normal activity for irritability/fussiness.”










observed to increase with consecutive doses, particularly follow-
ing the dose 3 booster vaccination. An increase in fever and
local injection site symptoms after the second vaccination has
been reported in some studies of AS03B-adjuvanted 2009
pandemic inﬂuenza A(H1N1) vaccine in young children [22;
Kosalaraksa et al., submitted]. No related SAEs or pIMDs
were reported during the study.
Recent reports have suggested that receipt of a 2009 pandem-
ic inﬂuenza A(H1N1) vaccine (using a strain distinct from the
one we used) or natural infection with inﬂuenza virus was
linked with subsequent onset of narcolepsy [23–33]. Recently,
CD4+ T cells from narcoleptic individuals with the HLA
DQ0602 allele have been shown to recognize an epitope unique
to the inﬂuenza A(H1N1) HA protein that mimics an epitope of
the hypocretin protein [34]. Further research will help to eluci-
date the chain of events that resulted in narcolepsy and the
potential roles of genetic and environmental factors. No cases
of narcolepsy were detected in this study.
Prime-boost schedules using H5N1-AS03 vaccines in adults
showed that rapid and robust immune responses to vaccine-
homologous and heterologous strains could be induced up to
15 months after priming [10, 11, 35]. A previous study estab-
lished that a lower dose of HA (1.9 μg) was immunogenic for
vaccine-homologous and heterologous strains in children 3–9
years of age, with acceptable reactogenicity and safety, compared
with unadjuvanted trivalent seasonal inﬂuenza vaccine [14]. Our
study extends these results to the population of infants and young
children from 6 months of age. Moreover we demonstrate the
effectiveness of primary vaccination using H5N1-AS03B in in-
fants and young children and the value of a heterologous booster
dose in boosting the immune response to related clade strains.
These results conﬁrm the potential usefulness of H5N1-AS03B
for children either in a prepandemic setting, to reduce attack
rates early on in a pandemic, or in an early pandemic setting,
where vaccination could prime or protect until a pandemic-
strain-matched vaccine becomes available.
A potential limitation of this study is the absence of a control
group, which precludes evaluation of common events such as
fever in a pediatric population. Another limitation is the absence
of efﬁcacy data against inﬂuenza A(H5N1) disease that conﬁrms
current regulatory cutoffs for inﬂuenza vaccines. The heterolo-
gous booster was given 6 months after priming. Immunogenicity
of a booster dose after a prolonged period after priming, as might
occur should prepandemic vaccination be performed, has been
assessed in adults but not yet in young children. A potential sin-
gle-dose priming approach in young children also warrants fur-
ther investigation in view of the possible pressures of vaccine
supply in a pandemic setting, with putatively adequate immune
responses following 2 doses of vaccine and increased reactogenic-
ity with a third dose of vaccine. Finally, A/Indonesia/05/2005 and
A/turkey/Turkey/1/2005 are related clade 2 strains (subclade 2.1
and 2.2, respectively) [36]. Although currently the majority of
human cases have been due to clade 2 strains [36], broader im-
munity would be needed should infecting strains emerge from
more distantly related clades.
In summary, this ﬁrst study of H5N1-AS03 in infants and
young children showed that a 2-dose series induced effective
priming in this age group. Subsequent vaccination with a heter-
ologous booster vaccine was immunogenic for both the homol-
ogous and heterologous strains. Reactogenicity appeared to
increase with increasing doses of adjuvanted vaccine. Signiﬁcant
fever (temperature, ≥39.0°C) was reported for 1 in 10 children
following booster vaccination, but no safety concerns were iden-
tiﬁed. The results support a prime-boost strategy for pandemic
preparedness. Prepandemic vaccination with a clade 2 strain
could be used in young children in the expectation that subse-
quent heterologous booster vaccination would boost immune
responses to a related clade 2 pandemic-speciﬁc virus strain.
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